| INTRODUC TI ON
Coronary artery disease (CAD) has become the major cause of death and illness worldwide. 1 According to the World Health Organization, CAD is the leading cause of death worldwide among all noncommunicable diseases. 2 Current therapeutic options are limited to pharmacological therapy, percutaneous coronary intervention, and bypass surgery; however, a large number of patients do not qualify for surgical or interventional procedures, and many patients have refractory angina despite maximal medical therapy. 3 These limitations have led to extensive research to find new treatment modalities.
Coronary artery disease causes a lack of coronary blood flow, and all therapeutic interventions should aim to improve blood flow to the ischemic myocardium. 4 Therapeutic angiogenesis represents a novel treatment option for patients with CAD
as it can increase blood flow and repair injured and dead myocardium. 5, 6 The vascular endothelial growth factor (VEGF) family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth factor (PLGF), which are key regulators of angiogenesis and lymphangiogenesis. There are two predominant isoforms of VEGF-A, VEGF-A121, and VEGF-A165, which are the most potent stimulators of angiogenic processes. VEGF-B plays a role in the maintenance of newly formed blood vessels under pathological conditions. VEGF-C and VEGF-D are primarily lymphangiogenic factors that can also induce angiogenesis. PLGF has a particular role in inflammatory responses and pathological permeability. [7] [8] [9] Currently, VEGF-A, VEGF-C, and VEGF-D are mainly used in CAD in clinical trials. 10, 11 Gene therapy is the therapeutic delivery of nucleic acid into cells to treat disease. In VEGF gene therapy, DNA encoding VEGF is transferred into cells in the ischemic myocardium, which subsequently grows new blood vessels; such therapy is a potential new treatment option. 12, 13 To date, this intriguing approach to using VEGF gene therapy for CAD has been pursued in several clinical trials, but the results have been inconsistent. 14, 15 Furthermore, several studies have suggested that VEGFs can accelerate the process of atherosclerosis in certain animal models and potentially destabilize coronary plaques. 16, 17 These findings contradict the effect of angiogenesis therapy on CAD, as most patients with CAD suffer from atherosclerosis. Hence, this therapy remains controversial, and there is no related meta-analysis. Therefore, we aimed to perform a systematic review and meta-analysis of the role of VEGF gene therapy for CAD.
| ME THODS

| Search strategy
This systematic review and meta-analysis are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Additionally, we registered the current meta-analysis at the international prospective register of systematic reviews (number: CRD42017058430). 18 We selected randomized controlled trials (RCTs) containing VEGF gene therapy published up to May 2018 by searching the PubMed, Embase, and Cochrane databases and relevant references.
Medical search terms included the following: "vascular endothelial growth factor gene" OR "VEGF gene" AND "coronary artery disease" OR "CAD" OR "coronary heart disease" OR "CHD" OR "angina" AND "randomized controlled trial." We also performed a manual search.
Two investigators (RY and QX) independently performed the database search and study selection.
| Inclusion and exclusion criteria
We considered studies for inclusion if they met all of the following criteria: (a) RCTs comparing VEGF gene therapy and standard treat- 
| Data extraction and management
Two independent investigators (RY and QX) reviewed the study and extracted the data. Any further calculations on study data were conducted by the first reviewer and checked by the second reviewer. 
| Quality assessment
The Cochrane Collaboration's tool for assessing risk of bias was used to assess the methodological quality of the included studies. The seven items in this tool address the adequacy of randomization and allocation concealment, blinding, completeness of outcome data, selective reporting, and other bias.
| Statistical analysis
The relative risk (RR) and 95% confidence interval (CI) were calculated to assess differences in mortality and serious cardiac events. 
| RE SULTS
| Description of included studies
A total of 524 studies were identified, and 124 records were removed because they were duplicates. By screening titles and abstracts, we excluded 375 records because they were experimental studies, review articles, non-CAD studies, or non-VEGF gene therapy studies.
By browsing full-text articles, we excluded 11 records for not being RCTs, not involving VEGF gene therapy, or having no outcome information. Finally, a total of 14 RCTs were included. 
| Risk of bias assessment
All the included studies were RCTs. 22, 25, 27 There was an unclear risk of bias in allocation concealment, blinding of outcome assessment, incomplete outcome data, and selective reporting. There was a high risk of bias in blinding ( Figure 2 ).
| Study characteristics
In this meta-analysis, 1 of the 13 articles contained two studies, and The mean trial duration was 6 months (range: 3-12 months). Table 1 shows the distribution of these studies according to study design, patient characteristics, treatment measures, and adverse effects.
| Primary outcome
The outcome measures were not reported in all of the trials. In this meta-analysis, seven studies assessed mortality. 13, 14, [19] [20] [21] [22] 24 There was no statistically significant difference in mortality between the VEGF gene therapy group and the control group (RR: 0.79; 95%CI: 0.29, 2.13; P = 0.64), although the subgroup analysis was performed on different VEGF gene types and vectors. We detected no significant heterogeneity ( Figure 3A ). The overall sample size was relatively small, and publication bias cannot be evaluated for mortality. In addition, In this meta-analysis, 10 studies assessed serious cardiac events. [13] [14] [15] [19] [20] [21] [22] 24, 26 Pooling data from these studies showed that VEGF gene therapy led to a significantly decreased risk of serious cardiac events (11.7% vs 21.2%, RR: 0.56; 95%CI: 0.37, 0.84; P = 0.005).
In the subgroup analysis, the risk of serious cardiac events was significantly lower in the VEGF-A165 gene therapy group (RR: 0.52; 95%CI: 0.30, 0.91) and in the adenovirus vector group (RR: 0.55; 95%CI: 0.31, 0.96). We detected no significant heterogeneity ( Figure 3B ). In this analysis, there was no significant publication bias (P = 0.94), and the funnel plot is shown in Figure 3C . 
| Secondary outcomes
In this meta-analysis, seven studies (N = 219 participants) assessed LVEF. 14 Figure 4B ). Publication bias could not be evaluated because of the relatively small sample size.
In this meta-analysis, seven studies assessed CCS angina class during a mean period of 6 months. 14, 15, 20, 21, 24, 26 There is no significant benefit of VEGF gene therapy on CCS angina class. In the subgroup analysis, the CCS angina class was significantly lower in 14.40, 21.60), and VEGF-A121 had no effect on angina frequency scores ( Figure 4D ).
| Sensitivity analyses
In sensitivity analyses, the pooled effect estimates showed no significant differences in follow-up LVEF upon excluding the study by Kastrup et al, 24 which indicated that this result was not robust.
Individual study exclusion did not substantially change the pooled effect estimate of other outcomes.
| Adverse effects
Five trials described the adverse effects in detail, 13, 15, 19, 20, 26 could not be fully investigated because of the small sample size, and the results require further validation. Overall, these data support the hypothesis that VEGF gene transfer, especially using adenoviral vectors, is a safe potential therapy for CAD that is beneficial in terms of serious cardiac events, albeit with no effect on mortality or angina frequency scores. Therefore, this meta-analysis highlights the need for further exploration in these areas.
Improving blood flow to the ischemic myocardium plays a critical role in the treatment of CAD. 4 VEGF-A165 and VEGF-A121 both induce angiogenesis and increase blood flow. VEGF-A165 is more highly expressed than VEGF-A121, while VEGF-A121 diffuses more into the ischemic milieu than VEGF-A165; VEGF-C and VEGF-D stimulate lymphatic vessel growth and do not directly stimulate inflammatory responses. 8, 13, [30] [31] [32] and treatment duration were taken into account; however, the heterogeneity was not eliminated, so these results should be interpreted cautiously.
Genes encoding VEGFs can be transfected into the myocardium by plasmid DNA or adenovirus vectors. 7, 33, 34 Recently, the use of adenovirus has gained popularity due to higher cardiac tropism and promising preclinical results. 34 Our results also showed that gene delivery using adenoviral vectors prompted improvements in serious cardiac events, ΔLVEF, and CCS angina class, which indicated that more efficient adenovirus transfection could be necessary to induce neovascularization in the ischemic myocardium.
In this meta-analysis, most of the trials reported no adverse effects, while two trials showed a significant difference in musculoskeletal pain, transient fever, and transient elevation of serum C-reactive protein between the two groups, 20, 26 which may be correlated with adverse effects of the VEGF-A gene. 35 Moreover, adenovirus vectors may increase the risk of inflammatory activation, while most of these adverse effects alleviated after discontinuing treatment. However, more attention still should be paid to the use of VEGF gene transfer for angiogenic diseases, such as atherosclerotic disease, rheumatoid disease, retinal disease, and malignant tumors. 29, 36, 37 Our meta-analysis has several limitations. First, differences in study design are likely to have introduced heterogeneity in ΔLVEF, CCS angina class, and angina frequency scores. Although we performed subgroup analyses, difference remained among the studies in terms of the sample size, race, religious beliefs, and concern regarding the disease. Second, most of the included studies had a relatively small sample size and might be methodologically less robust, potentially leading to overestimation of treatment effects. Third, the long-term persistence of the treatment effects is unknown. Most of the trials ranged in duration from 3 to 12 months, and only one trial reported long-term follow-up. 29 Fourth, the publication bias could not be evaluated in all outcomes because of small sample size. In the bias evaluation, we emailed all the corresponding authors, but unfortunately, only one author replied in detail. Finally, the ideal time to begin this treatment in the clinical course of the disease is unknown.
The outcomes and conclusions should be interpreted with these limitations in mind.
Therapeutic angiogenesis is still a promising new treatment for patients with CAD. However, more research, including large-scale, double-blind, randomized, placebo-controlled, multicenter trials with a standardized design, is needed to validate and verify the efficacy of VEGF gene therapy as a reliable supportive therapeutic option in CAD.
| CON CLUS ION
VEGF gene therapy appears to be associated with a reduction in serious cardiac events and a slight improvement in follow-up LVEF, and adenoviral vectors seem to have more benefit in terms of the risk of serious cardiac events, ΔLVEF, and CCS angina class and thus may be useful in proangiogenesis regimens for patients with CAD. However, further clinical trials are needed to establish the optimal approach for the application of this treatment in practice.
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